A phase i study of an oral simulated FOLFOX with high dose capecitabine

Investigational New Drugs

Volumn 27, Issue 5, 2009, Pages 461-468

  Mulkerin, D ^a   Loconte, N K ^a   Holen, K D ^a   Thomas, J P ^b   Alberti, D ^a   Marnocha, R ^a   Kolesar, J ^a   Eickhoff, J ^a   Oliver, K ^a   Feierabend, C ^a   Wilding, G ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

5 FU; Capecitabine; Chemotherapy; Oxaliplatin; Phase I

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; BOLUS INJECTION; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONFUSION; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; ESOPHAGUS CANCER; FATIGUE; FEMALE; GALLBLADDER CANCER; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPOTENSION; LIVER CANCER; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEAKNESS;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 70349235532     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9210-8     Document Type: Article

References (28)

1. A de Gramont JF Bosset C Milan, et al. 1997 Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study J Clin Oncol 15 2 808 815 9053508
2. CH Kohne P Schoffski H Wilke, et al. 1998 Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer J Clin Oncol 16 2 418 426 9469324 1:CAS:528:DyaK1cXhtFSht7k%3D
3. PJ O'Dwyer J Manola FH Valone, et al. 2001 Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule-an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study J Clin Oncol 19 9 2413 2421 11331320
4. NB Haas RJ Schilder S Nash, et al. 1995 A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer Invest New Drugs 13 3 229 233 8729951 10.1007/BF00873805 1:CAS:528:DyaK28XislKltr4%3D (Pubitemid 26091461)
5. CH Kohne J Wils M Lorenz, et al. 2003 Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952 J Clin Oncol 21 20 3721 3728 12963704 10.1200/JCO.2003.11.122 (Pubitemid 46606225)
6. A de Gramont A Figer M Seymour, et al. 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 16 2938 2947 10944126
7. RM Goldberg DJ Sargent RF Morton, et al. 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 1 23 30 14665611 10.1200/JCO.2004.09.046 1:CAS:528:DC%2BD2cXpsVKitbY%3D (Pubitemid 41095110)
8. C Tournigand T Andre E Achille, et al. 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2 229 237 14657227 10.1200/JCO.2004.05.113 1:CAS:528: DC%2BD2cXpsVKit7w%3D (Pubitemid 41095086)
9. T Ishikawa Y Fukase T Yamamoto F Sekiguchi H Ishitsuka 1998 Antitumor activities of a novel fluoropyrimidine, N4-pentyloxycarbonyl-5′-deoxy-5- fluorocytidine (capecitabine) Biol Pharm Bull 21 7 713 717 9703255 1:CAS:528:DyaK1cXkslyju78%3D
10. J Schuller J Cassidy E Dumont, et al. 2000 Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 4 291 297 10755317 10.1007/s002800050043 1:CAS:528:DC%2BD3cXhtlCrtLk%3D
11. Y Tsukamoto Y Kato M Ura, et al. 2001 A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU Pharm Res 18 8 1190 1202 11587492 10.1023/A:1010939329562 1:CAS:528:DC%2BD3MXnt1ektL4%3D (Pubitemid 32900406)
12. PM Hoff R Ansari G Batist, et al. 2001 Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study J Clin Oncol 19 8 2282 2292 11304782 1:CAS:528:DC%2BD3MXjsFeqsrw%3D
13. E Van Cutsem C Twelves J Cassidy, et al. 2001 Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study J Clin Oncol 19 21 4097 4106 11689577
14. J Cassidy J Tabernero C Twelves, et al. 2004 XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer J Clin Oncol 22 11 2084 2091 15169795 10.1200/JCO.2004.11.069 1:CAS:528:DC%2BD2cXpsVWlsL8%3D (Pubitemid 41095141)
15. W Scheithauer GV Kornek M Raderer, et al. 2003 Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 21 7 1307 1312 12663719 10.1200/JCO.2003.09.016 1:CAS:528:DC%2BD2cXpsVWqsLk%3D (Pubitemid 46606408)
16. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
17. LS Couch DL Groteluschen JA Stewart DL Mulkerin 2003 Capecitabine-related neurotoxicity presenting as trismus Clin Colorectal Cancer 3 2 121 123 12952569 10.3816/CCC.2003.n.019
18. D Renouf S Gill 2006 Capecitabine-induced cerebellar toxicity Clin Colorectal Cancer 6 1 70 71 16796795 10.3816/CCC.2006.n.024
19. YA Kim HC Chung HJ Choi SY Rha JS Seong HC Jeung 2006 Intermediate dose 5-fluorouracil-induced encephalopathy Jpn J Clin Oncol 36 1 55 59 16436463 10.1093/jjco/hyi214 (Pubitemid 43210736)
20. NA Pirzada II Ali RM Dafer 2000 Fluorouracil-induced neurotoxicity Ann Pharmacother 34 1 35 38 10669184 10.1345/aph.18425 1:STN:280: DC%2BD3c7jt1Klug%3D%3D
21. E Diaz-Rubio TR Evans J Tabemero, et al. 2002 Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors Ann Oncol 13 4 558 565 12056706 10.1093/annonc/mdf065 1:STN:280:DC%2BD38zhsVynsQ%3D%3D (Pubitemid 34461139)
22. C Twelves A Wong MP Nowacki, et al. 2005 Capecitabine as adjuvant treatment for stage III colon cancer N Engl J Med 352 26 2696 2704 15987918 10.1056/NEJMoa043116 1:CAS:528:DC%2BD2MXls1SktL0%3D (Pubitemid 41007824)
23. B Reigner K Blesch E Weidekamm 2001 Clinical pharmacokinetics of capecitabine Clin Pharmacokinet 40 2 85 104 11286326 10.2165/00003088-200140020- 00002 1:CAS:528:DC%2BD3MXislansrs%3D
24. SP Joel D Papamichael F Richards, et al. 2004 Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin Clin Pharmacol Ther 76 1 45 54 15229463 10.1016/j.clpt.2004.03.008 1:CAS:528:DC%2BD2cXlsVaqtrg%3D (Pubitemid 38844733)
25. SE Al-Batran A Atmaca S Hegewisch-Becker, et al. 2004 Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer J Clin Oncol 22 4 658 663 14966088 10.1200/JCO.2004.07. 042 1:CAS:528:DC%2BD2cXpsVajs7Y%3D (Pubitemid 41102130)
26. TH Cartwright A Cohn JA Varkey, et al. 2002 Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer J Clin Oncol 20 1 160 164 11773165 10.1200/JCO.20.1.160 1:CAS:528: DC%2BD38XnsFertA%3D%3D (Pubitemid 34032607)
27. YH Park BS Kim BY Ryoo SH Yang 2005 Oxaliplatin and capecitabine combination chemotherapy for patients with advanced gastric carcinoma: a pilot study results J Clin Oncol 23 16 357S-S
28. HQ Xiong RA Wolff KR Hess GR Varadhachary JC Blais JL Abbruzzese 2006 A phase II trial of oxaliplatin plus capecitabine (xelox) as second line therapy for patients with advanced pancreatic cancer J Clin Oncol 24 18 207S-S